tiotropium 5mcg/day

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Asthma

Phase 3

Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)

CompletedNCT00772538

Boehringer IngelheimAsthma

Start: 2008-10-31Updated: 2014-08-18

Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)

CompletedNCT00776984

Boehringer IngelheimAsthma

Start: 2008-10-31Updated: 2014-09-10

Related Papers

Peak expiratory flow as an endpoint for clinical trials in asthma: a comparison with FEV<sub>1</sub>.

2019-07-1817 citations

Safety of tiotropium Respimat<sup>®</sup> in black or African-American patients with symptomatic asthma.

2019-07-022 citations

S106 Tiotropium respimat® reduces episodes of asthma worsening in primotina-asthma®, irrespective of baseline characteristics or season

2018-11-16

Tiotropium Respimat Add-on Is Efficacious in Symptomatic Asthma, Independent of T2 Phenotype.

2017-11-2253 citations

P86 In vitro and clinical characterisation of the antistatic valved holding chamber aerochamber plus® flow-vu® for administrating tiotropium respimat® in 1–5-year-old children with persistent asthmatic symptoms

2017-11-15

Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status

Respiratory Medicine2016-06-18100 citations

P151 Tiotropium Respimat® add-on therapy reduces exacerbation risk in patients with moderate or severe symptomatic asthma, independent of TH2 status: Abstract P151 Table 1

Thorax2015-11-121 citations

P150 Once-daily tiotropium Respimat® reduces risk of severe asthma exacerbation and asthma worsening in symptomatic asthma, independent of allergic and inflammatory status

Thorax2015-11-12

P231 Once-daily Tiotropium Respimat(R): Safety And Tolerability Results From Five Phase Iii Trials In Adults With Symptomatic Asthma

Thorax2014-11-102 citations

S91 Once-daily tiotropium Respimat(R) add-on to ICS + LABA improves symptom control and reduces exacerbations in patients with symptomatic asthma

Thorax2014-11-101 citations

S92 Efficacy Of Once-daily Tiotropium Respimat(R) 5 g From Five Phase Iii Trials In Adults With Symptomatic Asthma

Thorax2014-11-101 citations

P230 Once-daily Tiotropium Respimat(R) Improves Lung Function In Patients With Severe Symptomatic Asthma Independent Of Leukotriene Modifier Use

Thorax2014-11-101 citations

Tiotropium in asthma poorly controlled with standard combination therapy.

2012-09-02440 citations